Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.
Andrew M. Evens(Rutgers, The State University of New Jersey), Nancy L. Bartlett(Washington University in St. Louis), Martha Guerra(Revolution Medicines (United States)), Weiyun Z. Ai(City College of San Francisco), Ahmed Hamdy(Pharmacyclics (United States)), Chitra Mani(Pharmacyclics (United States)), Joseph J. Buggy(Pharmacyclics (United States)), Sriram Balasubramanian(Pharmacyclics (United States)), Julie M. Vose(University of Nebraska Medical Center), Nancy Szakacs(Pharmacyclics (United States)), David Loury(Pharmacyclics (United States)), Mint Sirisawad(Pharmacyclics (United States))
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k